Moderna appoints former executive Juan Andres as COO as Neurocrine reshuffles leadership; Pharming CEO steps down after board dispute

Juan Andres, a former Moderna executive, will return from retirement to assume the role of chief operating officer on Oct. 5. His deep familiarity with the company is seen as valuable as Moderna advances its cancer vaccine program developed in partnership with Merck.

The appointment comes as Moderna continues to build momentum in clinical trials for the vaccine, aiming to expand its oncology pipeline beyond its mRNA COVID-19 products.

In related leadership news, Neurocrine Biosciences also announced the return of previous executives to key positions, though details were limited.

Separately, Pharming announced that its chief executive officer will leave the company following a disagreement with the board, indicating potential governance challenges.